{"nctId":"NCT00768287","briefTitle":"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B","startDateStruct":{"date":"2009-01","type":"ACTUAL"},"conditions":["Hemophilia B"],"count":77,"armGroups":[{"label":"IB1001","type":"EXPERIMENTAL","interventionNames":["Biological: IB1001"]},{"label":"nonacog alfa","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: nonacog alfa"]}],"interventions":[{"name":"IB1001","otherNames":["Recombinant factor IX (rFIX)","IXINITY"]},{"name":"nonacog alfa","otherNames":["Recombinant factor IX (rFIX)","BeneFIX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patient must be willing to give written Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent, make the required study visits, and follow instructions while enrolled in the study\n2. Severe (factor IX activity ≤2 U/dL) hemophilia B subjects on demand therapy with a minimum of 3 bleeding episodes over the preceding 6 months or 6 bleeding episodes over the preceding 12 months; subjects on prophylaxis with a bleeding pattern as above demonstrated prior to starting prophylaxis\n3. Immunocompetent (CD4 count \\>400/mm3) and not receiving immune modulating or chemotherapeutic agents\n4. Previously treated patients with a minimum of 150 exposure days to a factor IX preparation\n5. Platelet count at least 150,000/mm3\n6. Liver function: alanine transaminase \\[ALT\\] and aspartate transaminase \\[AST\\] ≤2 times the upper limit of the normal range\n7. Total bilirubin ≤1.5 times the upper limit of the normal range\n8. Renal function: serum creatinine ≤1.25 times the upper limit of the normal range\n9. Willingness to participate in the trial for up to 12-15 months\n10. European Union (EU), Israel, and Canada: Age of at least 12 years and body weight of ≥40 kilograms to participate in any PK Study or the Surgical Sub-study \\[the Surgical Sub-study does not apply to the UK\\]; age of at least 12 years for the prophylaxis and on demand components of the Treatment Phase and Continuation Study\n\n    United States (US): Age of at least 12 years and body weight of ≥40 kilograms to participate in any PK Study or the Surgical Sub-study; age of at least 5 years for the prophylaxis and on demand components of the Treatment Phase and Continuation Study\n11. Hemoglobin ≥7 g/dL at the time of the blood draw\n\nExclusion Criteria:\n\n1. History of factor IX inhibitor ≥0.6 Bethesda units (BU)\n2. Existence of another coagulation disorder\n3. Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular coagulation (DIC)\n4. Use of an investigational drug within 30 days prior to study entry\n5. On medications that could impact hemostasis, such as aspirin\n6. History of poor compliance, a serious medical or social condition, or any other circumstance that, in the opinion of the investigator, would interfere with participation or compliance with the study protocol\n7. History of adverse reaction to either plasma-derived factor IX or recombinant factor IX that interfered with the subject's ability to treat bleeding episodes with a factor IX product","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Degree of Hemorrhage Control by Treatment Regimen","description":"Subject rating of bleed control within 6 hours of the time bleeding has stopped:\n\n1. Excellent: a dramatic response with abrupt pain relief and clear reduction in joint or hemorrhage site size;\n2. Good: pain relief or reduction in hemorrhage site size that may have required an additional infusion for resolution;\n3. Fair: probable or slight beneficial response usually requiring one or more additional infusions for resolution;\n4. Poor: no improvement or condition worsens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"116","spread":null}]},{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"74","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"28","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (0-inf)","description":"Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1572.5","spread":"451.5"},{"groupId":"OG001","value":"1656.5","spread":"468.6"},{"groupId":"OG002","value":"1530.0","spread":"435.4"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (0-72 hr)","description":"Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1374.6","spread":"356.4"},{"groupId":"OG001","value":"1414.5","spread":"339.4"},{"groupId":"OG002","value":"1355.9","spread":"381.2"}]}]}]},{"type":"SECONDARY","title":"Terminal Half-life","description":"Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"6.9"},{"groupId":"OG001","value":"26.4","spread":"13.6"},{"groupId":"OG002","value":"24.2","spread":"6.3"}]}]}]},{"type":"SECONDARY","title":"Concentration (Max)","description":"Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","spread":"16.6"},{"groupId":"OG001","value":"72.8","spread":"17.5"},{"groupId":"OG002","value":"72.7","spread":"15.2"}]}]}]},{"type":"SECONDARY","title":"Incremental Recovery","description":"Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"0.21"},{"groupId":"OG001","value":"0.94","spread":"0.23"},{"groupId":"OG002","value":"0.94","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Mean Residence Time","description":"Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":"6.4"},{"groupId":"OG001","value":"35.4","spread":"13.1"},{"groupId":"OG002","value":"30.5","spread":"5.0"}]}]}]},{"type":"SECONDARY","title":"Clearance","description":"Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.051","spread":"0.013"},{"groupId":"OG001","value":"0.050","spread":"0.012"},{"groupId":"OG002","value":"0.052","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Volume of Distribution (Steady State)","description":"Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"0.57"},{"groupId":"OG001","value":"1.81","spread":"0.57"},{"groupId":"OG002","value":"1.85","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Annualized Bleed Rate","description":"Measure was assessed during the Treatment Study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.10","spread":null},{"groupId":"OG001","value":"1.52","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blood Loss During Surgery","description":"Surgeon assessment of blood loss during the procedure using the following descriptors: less than expected, expected, or more than expected. Measure was assessed during Surgical Substudy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hemostasis Following Surgery","description":"Surgeon assessment of hemostasis at 12 and 24 hours after surgery using the following descriptors: superior, adequate, or poorly controlled. Measure was assessed during Surgical Substudy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Surgeries Requiring Blood Transfusions","description":"Measure was assessed during Surgical Substudy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":77},"commonTop":["Headache","Arthralgia","Pyrexia","Nasopharyngitis","Limb injury"]}}}